Catalyzing the critical path initiative: FDA's progress in drug development activities-Reference-Cited by-同舟云学术

Catalyzing the critical path initiative: FDA's progress in drug development activities

Published:2015-01-28 Issue:3 Volume:97 Page:221-233
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Parekh A¹,Buckman-Garner S¹,McCune S¹,ONeill R¹,Geanacopoulos M¹,Amur S¹,Clingman C¹,Barratt R¹,Rocca M¹,Hills I¹,Woodcock J²

Affiliation:

1. Office of Translational Sciences, Center for Drug Evaluation and Research; US Food and Drug Administration; Silver Spring Maryland USA

2. Center for Drug Evaluation and Research; US Food and Drug Administration; Silver Spring Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.42/fullpdf

Reference74 articles.

1. FDA http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html 2004

2. http://www.fda.gov/Drugs/GuidancecomplianceRegulatoryInformation/Guidances/default.htm

3. FDA. Critical Path Opportunities Report http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077254.pdf 2006

4. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077258.pdf 2006

5. st http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/default.htm

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics;Cancers;2023-06-18

2. The Role of fMRI in Drug Development: An Update;Advances in Neurobiology;2023

3. Huntington’s Disease Regulatory Science Consortium: Accelerating Medical Product Development;Journal of Huntington's Disease;2022-06-03

4. Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery;Frontiers in Pharmacology;2020-06-30

5. Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states;European Journal of Pharmaceutical Sciences;2019-10